RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018
May 30, 2018 08:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty...
RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy
May 29, 2018 08:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy
May 29, 2018 08:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15
May 14, 2018 08:00 ET
|
RedHill Biopharma Ltd.
Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV,...
RedHill Biopharma Reports First Quarter 2018 Financial Results
May 08, 2018 07:00 ET
|
RedHill Biopharma Ltd.
Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 monthsTop-line results from confirmatory Phase III study with...
RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease
May 07, 2018 08:00 ET
|
RedHill Biopharma Ltd.
Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months Worldwide sales of Crohn’s disease therapies are estimated to...
RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
May 04, 2018 07:00 ET
|
RedHill Biopharma Ltd.
Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to...
RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018
May 01, 2018 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
RedHill Biopharma Provides Semi-Annual Business Update
April 09, 2018 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., April 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
March 27, 2018 08:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...